By
Drug Target Review2025-05-27T08:30:09
Researchers at Mass General Brigham have developed a new gene therapy delivery system, AAV.CPP.16, that targets the lungs via nasal spray, which could offer a potential breakthrough in respiratory gene therapy.
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2023-11-20T13:43:43
Sponsored by Merck
2024-01-19T07:40:55
Sponsored by Euretos
2023-03-28T11:38:32
Sponsored by Bio-Techne
2023-03-07T10:55:58
Sponsored by Agilent
2023-01-05T14:41:33
Sponsored by Cell Signaling Technology
Site powered by Webvision Cloud